Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00259-017-3821-2PMID 28894897
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Classification of neuroendocrine neoplasms of the digestive system

  2019cited by this paper
• 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

  2017cited by this paper
• High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours

  2017cited by this paper
• 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

  2017cited by this paper
• Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors

  2017cited by this paper
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

  2017cited by this paper
• 177Lu-Dotatate for Midgut Neuroendocrine Tumors

  2017cited by this paper
• Everolimus in Pancreatic Neuroendocrine Carcinomas G3

  2017cited by this paper
• ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

  2016cited by this paper
• A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas

  2016cited by this paper
• The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories

  2016cited by this paper
• Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours

  2015cited by this paper
• Treatment of high grade metastatic neuroendocrine tumor (mNET) with peptide receptor radionuclide therapy (PRRT): Retrospective analysis in a single referral center.

  2015cited by this paper
• Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.

  2015cited by this paper
• Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas

  2015cited by this paper
• Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)

  2014cited by this paper
• Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?

  2014cited by this paper
• Hematological Toxicity of Combined 177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up

  2014cited by this paper
• The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

  2013influential reference
• Are G3 ENETS neuroendocrine neoplasms heterogeneous?

  2013cited by this paper
• Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

  2013cited by this paper
• Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

  2013cited by this paper
• Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion

  2013influential reference
• Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.

  2013cited by this paper
• Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2012cited by this paper
• Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors

  2012cited by this paper
• Changing paradigms with molecular imaging of neuroendocrine tumors.

  2012cited by this paper
• Clinical effect of temozolomide‐based chemotherapy in poorly differentiated endocrine carcinoma after progression on first‐line chemotherapy

  2011cited by this paper
• First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

  2011cited by this paper
• Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

  2011cited by this paper
• Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

  2011cited by this paper
• 3. The ENETS Guidelines: The New TNM Classification System

  2010cited by this paper
• Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated ( High-Grade ) Extrapulmonary Neuroendocrine Carcinomas

  2010cited by this paper
• 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide

  2010cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors

  2009cited by this paper
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

  2009cited by this paper
• High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience

  2009cited by this paper
• From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

  2009cited by this paper
• Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

  2008cited by this paper
• The role of PET in monitoring therapy

  2005cited by this paper

• Peptide receptor radionuclide therapy (PRRT) in high grade neuroendocrine neoplasms: a systematic review and meta-analysis.

  2026cites this paper
• A nomogram for predicting surgery outcome of tumor-induced osteomalacia: a case-control study

  2025cites this paper
• ¹⁸F-AlF-NOTA-octreotide PET/CT in high-grade G3 neuroendocrine tumors and neuroendocrine carcinomas: diagnostic performance and complementarity with ¹⁸F-FDG PET/CT

  2025cites this paper
• Peptide receptor radionuclide therapy in malignant insulinoma.

  2025cites this paper
• Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives.

  2024cites this paper
• Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience

  2024cites this paper
• Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update

  2024cites this paper
• Imaging of Neuroendocrine Neoplasms; Principles of Treatment Strategies. What Referring Clinicians Want to Know

  2024cites this paper
• Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives

  2024cites this paper
• Clinical diagnosis and treatment of 37 cases of gallbladder neuroendocrine carcinoma

  2024cites this paper
• Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy

  2024cites this paper
• Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs.

  2024cites this paper
• Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Ass

  2024cites this paper
• Peptide receptor radionuclide therapy for ectopic Cushing’s syndrome caused by metastatic neuroendocrine neoplasms

  2024cites this paper
• Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023

  2024cites this paper
• Sequencing of Somatostatin-Receptor–Based Therapies in Neuroendocrine Tumor Patients

  2024cites this paper
• Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3

  2024cites this paper
• Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies

  2024cites this paper
• Liver Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms

  2024cites this paper
• European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma

  2023cites this paper
• Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea

  2023cites this paper
• Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging

  2023cites this paper
• Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade

  2023cites this paper
• Epidemiology and management of neuroendocrine neoplasms of unknown origin: an overview

  2023cites this paper
• Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review

  2023cites this paper
• European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours

  2023cites this paper
• Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience

  2023cites this paper
• Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms

  2023cites this paper
• Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements

  2023cites this paper
• Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE

  2023cites this paper
• Tumour Heterogeneity and the Consequent Practical Challenges in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms

  2023cites this paper
• Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?

  2023cites this paper
• Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: Actinium-225-DOTATATE and Combined Therapies.

  2023cites this paper
• Integrating Functional Imaging and Molecular Profiling for Optimal Treatment Selection in Neuroendocrine Neoplasms (NEN)

  2023cites this paper
• Molecular imaging Theranostics of Neuroendocrine Tumors.

  2023cites this paper
• Neuroendokrine Tumoren des Pankreas

  2023cites this paper
• The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?

  2022cites this paper
• Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues

  2022cites this paper
• Peptide Receptor Radionuclide Therapy

  2022cites this paper
• PRRT for higher-grade neuroendocrine neoplasms: What is still acceptable?

  2022cites this paper
• Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?

  2022cites this paper
• Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice

  2022cites this paper
• Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE

  2022cites this paper
• Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise

  2022cites this paper
• Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.

  2022cites this paper
• Real‐world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours

  2022cites this paper
• New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms

  2022cites this paper
• Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance

  2022cites this paper
• Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies

  2022cites this paper
• Letter to Editor Re: "Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms" (https://doi.org/10.1016/j.acra.2021.10.004).

  2022cites this paper
• Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors

  2022cites this paper
• Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides—Where Are We Now

  2022cites this paper
• Metastatic Grade 3 Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 Expressing Somatostatin Receptors.

  2022cites this paper
• Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions

  2022cites this paper
• Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response-AJR Expert Panel Narrative Review.

  2022cites this paper
• Therapiekonzepte bei fernmetastasierten GEP-NEN – medikamentöse und interventionelle Therapie

  2021cites this paper
• Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.

  2021cites this paper
• Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy

  2021cites this paper
• Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review

  2021cites this paper
• CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas

  2021cites this paper
• Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis

  2021cites this paper
• Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3)

  2021cites this paper
• Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?

  2021cites this paper
• Résultats et perspectives des traitements par Lutathera des tumeurs neuroendocrines à l’hôpital de Beaujon, centre RENATEN

  2021cites this paper
• High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Improved Prognostic Stratification With the New World Health Organization 2019 Classification

  2021cites this paper
• State of the art and future directions in the systemic treatment of neuroendocrine neoplasms

  2021cites this paper
• Radionuclide imaging of NENs

  2021cites this paper
• Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma

  2021cites this paper
• Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications

  2021cites this paper
• Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.

  2021cites this paper
• Increase of Ki‐67 index and influence on mortality in patients with neuroendocrine neoplasms

  2021cites this paper
• A Peptide Meets a Radionuclide to Combat a Rare Tumor

  2021cites this paper
• Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.

  2021cites this paper
• Combination Therapies with PRRT

  2021cites this paper
• PET Imaging in Neuro-Endocrine Neoplasms (NEN)

  2021cites this paper
• The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

  2020cites this paper
• Accelerating precision medicine in metastatic prostate cancer

  2020cites this paper
• Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors

  2020cites this paper
• Liver-Directed Therapy for Gastroenteropancreatic NETs in the Era of Peptide Receptor Radionuclide Therapy

  2020cites this paper
• Understanding the Treatment Algorithm of Patients with Metastatic Pancreatic Neuroendocrine Neoplasms: A Single-Institution Retrospective Analysis Comparing Outcomes of Chemotherapy, Molecular Targeted Therapy, and Peptide Receptor Radionuclide Therapy in 255 Patients

  2020cites this paper
• The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors

  2020cites this paper
• Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights

  2020cites this paper
• Peptide receptor radionuclide therapy as a two-step strategy for initially unresectable liver disease from neuroendocrine tumors: a single-center experience

  2020cites this paper
• Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.

  2020cites this paper
• Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2020cites this paper
• Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy

  2020cites this paper
• Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent 177Lu-DOTATOC therapy

  2020cites this paper
• NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy

  2020cites this paper
• OTT_A_202867 3545..3555

  2020cites this paper
• Current Status and Growth of Nuclear Theranostics in Singapore

  2019cites this paper
• Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms

  2019influential citation
• Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.

  2019cites this paper
• Twelve-Year Survival of a Patient With Lymph Node, Pulmonary, Bone, Cardiac and Intraspinal Metastases of a Rectal Neuroendocrine Neoplasm Treated With Peptide Receptor Radionuclide Therapy-The Value of Salvage Peptide Receptor Radionuclide Therapy.

  2019cites this paper
• Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: A step-by-step approach.

  2019cites this paper
• Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients

  2019cites this paper
• The Proceedings of the 19th International Cancer Imaging Society Meeting and Annual Teaching Course

  2019cites this paper
• Peptide Receptor Radiotherapy: Current Approaches and Future Directions

  2019cites this paper
• Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge

  2019cites this paper
• Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors

  2019cites this paper
• Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms

  2019cites this paper